Skip to main content
SpringerLink
Log in

Cancer du pancréas exocrine

  • Chapter
Les cancers digestifs

Part of the book series: Oncologie Pratique ((ONCOLPRAT))

  • 329 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Références

  1. Ducreux M, Boige V, Malka D (2004) Emerging drugs in pancreatic cancer. Expert Opin Emerg Drugs 9: 73–89

    Article  CAS  PubMed  Google Scholar 

  2. Li D, Xie K, Wolff R, Abbruzzese JL (2004) Pancreatic cancer. Lancet 363: 1049–57

    Article  CAS  PubMed  Google Scholar 

  3. Ducreux M, Saradet A, François E et al. (1998) Cancer du pancréas. In: Fédération nationale des centres de lutte contre le cancer (ed) Standards, options et recommandations. Cancers digestifs. II. Pancréas, rectum. John Libbey Eurotext, Montrouge, p 3

    Google Scholar 

  4. Société nationale française de gastro-entérologie (2001) Thesaurus de bonnes pratiques du cancer du pancréas exocrine. http://www.snfge.asso.fr/01-Bibliotheque/0G-Thesauruscancerologie/TPC-exocrine/sommaire.asp

    Google Scholar 

  5. Bourguet P, groupe de travail SOR (2003) Standards, Options et Recommandations 2002 pour l’utilisation de la tomographie par émission de positons au [18F]-FDG (TEP-FDG) en cancérologie (rapport intégral). Bull Cancer 90 Spec. N.: S5–17

    PubMed  Google Scholar 

  6. Nieveen van Dijkum EJ, Romijn MG, Terwee CB et al. (2003) Laparoscopic staging and subsequent palliation in patients with peripancreatic carcinoma. Ann Surg 237: 66–73

    PubMed  Google Scholar 

  7. Hoffman JP, Weese JL, Solin LJ et al. (1995) A pilot study of preoperative chemoradiation for patients with localized adenocarcinoma of the pancreas. Am J Surg 169: 71–8

    Article  CAS  PubMed  Google Scholar 

  8. Spitz FR, Abbruzzese JL, Lee JE et al. (1997) Preoperative and postoperative chemoradiation strategies in patients treated with pancreaticoduodenectomy for adenocarcinoma of the pancreas. J Clin Oncol 15: 928–37

    CAS  PubMed  Google Scholar 

  9. Snady H, Bruckner H, Cooperman A et al. (2000) Survival advantage of combined chemoradiotherapy compared with resection as the initial treatment of patients with regional pancreatic carcinoma. An outcome trial. Cancer 89: 314–27

    Article  CAS  PubMed  Google Scholar 

  10. Sohn TA, Lillemoe KD, Cameron JL et al. (1999) Reexploration for periampullary carcinoma: resectability, perioperative results, pathology, and long-term outcome. Ann Surg 229: 393–400

    Article  CAS  PubMed  Google Scholar 

  11. Bakkevold KE, Arnesjo B, Dahl O et al. (1993) Adjuvant combination chemotherapy (AMF) following radical resection of carcinoma of the pancreas and papilla of Vater — results of a controlled, prospective, randomised multicentre study. Eur J Cancer 29: A698–703

    Article  Google Scholar 

  12. Takada T, Amano H, Yasuda H et al. (2002) Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma. Cancer 95: 1685–95

    PubMed  Google Scholar 

  13. Neoptolemos JP, Stocken DD, Friess H et al. (2004) A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 350: 1200–10

    Article  CAS  PubMed  Google Scholar 

  14. Neoptolemos JP, Dunn JA, Stocken DD et al. (2001) Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet 358: 1576–85

    Article  CAS  PubMed  Google Scholar 

  15. Gastrointestinal Tumor Study Group (1987) Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Cancer 59: 2006–10

    Google Scholar 

  16. Kalser MH, Ellenberg SS (1985) Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg 120: 899–903

    CAS  PubMed  Google Scholar 

  17. Moertel CG, Frytak S, Hahn RG et al. (1981) Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 Rads) radiation alone, moderate dose radiation (4000 Rads + 5-fluoro-uracil), and high dose radiation + 5-fluoro-uracil. The Gastrointestinal Tumor Study Group. Cancer 48: 1705–10

    CAS  PubMed  Google Scholar 

  18. Klinkenbijl HL, Jeekel J, Sahmoud T et al. (1999) Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg 230: 776–82

    Article  CAS  PubMed  Google Scholar 

  19. Dunn JA, Stocken DD, Almond J et al. (2002) Meta-analysis of adjuvant chemoradiotherapy and chemotherapy for resectable pancreatic cancer including the final results of the ESPAC-1 trial. Proc Am Soc Clin Oncol: A564

    Google Scholar 

  20. Wong GY, Schroeder DR, Carns PE et al. (2004) Effect of neurolytic celiac plexus block on pain relief, quality of life, and survival in patients with unresectable pancreatic cancer: a randomized controlled trial. JAMA 291: 1092–9

    CAS  PubMed  Google Scholar 

  21. Moses AW, Slater C, Preston T et al. (2004) Reduced total energy expenditure and physical activity in cachectic patients with pancreatic cancer can be modulated by an energy and protein dense oral supplement enriched with n-3 fatty acids. Br J Cancer 90: 996–1002

    Article  CAS  PubMed  Google Scholar 

  22. Fearon KC, Von Meyenfeldt MF, Moses AG et al. (2003) Effect of a protein and energy dense N-3 fatty acid enriched oral supplement on loss of weight and lean tissue in cancer cachexia: a randomised double blind trial. Gut 52: 1479–86

    Article  CAS  PubMed  Google Scholar 

  23. Prat F, Chapat O, Ducot B et al. (1998) Predictive factors for survival of patients with inoperable malignant distal biliary strictures: a practical management guideline. Gut 42: 76–80

    CAS  PubMed  Google Scholar 

  24. Smith AC, Dowsett JF, Russell RC et al. (1994) Randomised trial of endoscopic stenting versus surgical bypass in malignant low bileduct obstruction. Lancet 344: 1655–60

    CAS  PubMed  Google Scholar 

  25. Lévy P, Hammel P, O’Toole D et al. (2002) Survie des malades ayant un adénocarcinome non résécable: les données de la littérature sont rendues caduques par les nouvelles modalités thérapeutiques. Gastroenterol Clin Biol 26: A53

    Google Scholar 

  26. Shinchi H, Takao S, Noma H et al. (2002) Length and quality of survival after externalbeam radiotherapy with concurrent continuous 5-fluoro-uracil infusion for locally unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys 53: 146–50

    Article  CAS  PubMed  Google Scholar 

  27. Klaassen DJ, MacIntyre JM, Catton GE et al. (1985) Treatment of locally unresectable cancer of the stomach and pancreas: a randomized comparison of 5-fluoro-uracil alone with radiation plus concurrent and maintenance 5-fluoro-uracil. An ECOG study. J Clin Oncol 3: 373–8

    CAS  PubMed  Google Scholar 

  28. Gastro-Intestinal Tumor Study Group (GITSG) (1988) Treatment of locally unresectable carcinoma of the pancreas: comparison of combined modality therapy (chemotherapy plus radiotherapy to chemotherapy alone). J Natl Cancer Inst 80: 751–5

    Google Scholar 

  29. Moertel CG, Childs DS, Reitemeier RJ et al. (1969) Combined 5-fluoro-uracil and supervoltage radiation therapy of locally unresectable gastrointestinal cancer. Lancet: 2865–7

    Google Scholar 

  30. Rich TA, Harris J, Abrams R et al. (2001) A phase II study of external irradiation and weekly paclitaxel for non-metastatic, unresectable pancreatic cancer: a preliminary report of RTOG protocol 98–12. Int J Radiat Oncol Biol Phys 51: 29

    Article  Google Scholar 

  31. Willett CG, Safran H, Abrams RA et al. (2003) Clinical research in pancreatic cancer: the Radiation Therapy Oncology Group trials. Int J Radiat Oncol Biol Phys 56: 31–7

    Article  PubMed  Google Scholar 

  32. Li CP, Chao Y, Chi KH et al. (2003) Concurrent chemoradiotherapy treatment of locally advanced pancreatic cancer: gemcitabine versus 5-fluoro-uracil, a randomized controlled study. Int J Radiat Oncol Biol Phys 57: 98–104

    Article  CAS  PubMed  Google Scholar 

  33. André T, Hammel P, Selle F et al. (2001) Multicentric GERCOR feasability study of bimonthly combination of leucovorin-5-FU and gemcitabine (6 cycles) followed by chemoradiotherapy (CRT) with 5-FU for locally advanced non metastatic pancreatic adenocarcinoma. Proc Am Clin Oncol 20: 155a (abst 616)

    Google Scholar 

  34. Mallinson CN, Rake MO, Cocking JB et al. (1980) Chemotherapy in pancreatic cancer: results of a controlled, prospective, randomized, multicentre trial. BMJ 281: 1589–91

    CAS  PubMed  Google Scholar 

  35. Cullinan SA, Moertel CG, Wieand HS et al. (1990) A phase III trial on the therapy of advanced pancreatic carcinoma. Evaluations of the Mallinson regimen and combined 5-fluoro-uracil, doxorubicin, and cisplatin. Cancer 65: 2207–12

    CAS  PubMed  Google Scholar 

  36. Palmer KR, Kerr M, Knowles G et al. (1994) Chemotherapy prolongs survival in inoperable pancreatic carcinoma. Br J Surg 81: 882–5

    CAS  PubMed  Google Scholar 

  37. Glimelius B, Hoffman K, Sjöden PO et al. (1996) Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol 7: 593–600

    CAS  PubMed  Google Scholar 

  38. Fung MC, Ishiguro H, Takayama S et al. (2003) Survival benefit of chemotherapy in advanced pancreatic cancer: a meta-analysis. Proc Am Soc Clin Oncol 22: A288 (abstr 1156)

    Google Scholar 

  39. Burris HAI, Moore JA, Andersen J et al. (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15: 2403–13

    CAS  PubMed  Google Scholar 

  40. Storniolo AM, Enas NH, Brown CA et al. (1999) An investigational new drug treatment program for patients with gemcitabine: results for over 3000 patients with pancreatic carcinoma. Cancer 85: 1261–8

    Article  CAS  PubMed  Google Scholar 

  41. Berlin JD, Catalano P, Thomas JP et al. (2002) Phase III study of gemcitabine in combination with fluoro-uracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol 20: 3270–5

    Article  CAS  PubMed  Google Scholar 

  42. Bramhall SR, Rosemurgy A, Brown PD et al. (2001) Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomised trial. J Clin Oncol 19: 3447–55

    CAS  PubMed  Google Scholar 

  43. Bramhall SR, Schulz J, Nemunaitis J et al. (2002) A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br J Cancer 87: 161–7

    Article  CAS  PubMed  Google Scholar 

  44. Cheverton P, Friess H, Andras C et al. (2004) Phase III results of exatecan (DX-8951f) versus gemcitabine in chemotherapy-naive patients with advanced pancreatic cancer. Proc Am Soc Clin Oncol 23: (abstract 4005)

    Google Scholar 

  45. Colucci G, Giuliani F, Gebbia V et al. (2002) Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologia dell’Italia Meridionale. Cancer 94: 902–10

    Article  CAS  PubMed  Google Scholar 

  46. Heinemann V, Quietzsc F, Gieseler F et al. (2003) A phase III trial comparing gemcitabine plus cisplatin vs gemcitabine alone in advanced pancreatic cancer. Proc Am Soc Clin Oncol 22: A 250 (abstract 1003)

    Google Scholar 

  47. Louvet C, Labianca R, Hammel P et al. (2004) GemOx (gemcitabine + oxaliplatin) versus gemcitabine in non resectable pancreatic adenocarcinoma: final results of the GERCOR/GISCAD Intergroup Phase III. Proc Am Soc Clin Oncol 23 (abstract 4008)

    Google Scholar 

  48. O’Reilly EM, Abou-Alfa GK, Letourneau R et al. (2004) A randomized phase III trial of DX-8951f (exatecan mesylate; DX) and gemcitabine (GEM) versus gemcitabine alone in advanced pancreatic cancer (APC). J Clin Oncol 2214S: 4006

    Google Scholar 

  49. Moore MJ, Hamm J, Dancey J et al. (2003) Comparison of Gemcitabine Versus the Matrix Metalloproteinase Inhibitor BAY 12-9566 in Patients With Advanced or Metastatic Adenocarcinoma of the Pancreas: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 21: 3296–302

    CAS  PubMed  Google Scholar 

  50. Reni M, Cordio S, Passardi A et al. (2004) Final results of a phase III trial of gemcitabine versus PEFG regimen in stage IVA or metastatic pancreatic adenocarcinoma. J Clin Oncol 2214S: 4010

    Google Scholar 

  51. Richards DA, Kindler HL, Oettle H et al. (2004) A randomized phase III study comparing gemcitabine plus pemetrexed versus gemcitabine in patients with locally advanced and metastatic pancreas cancer. J Clin Oncol 2214S: 4007

    Google Scholar 

  52. Rocha Lima CM, Green MR, Rotche R et al. (2004) Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol 22: 3776–83

    Article  CAS  PubMed  Google Scholar 

  53. Van Cutsem E, van de Velde H, Karasek P et al. (2004) Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol 22: 1430–8

    PubMed  Google Scholar 

  54. Touroutoglou N, Gravel D, Raber MN et al. (1998) Clinical results of a pharmacodynamically-based strategy for higher dosing of gemcitabine in patients with solid tumors. Ann Oncol 9: 1003–8

    Article  CAS  PubMed  Google Scholar 

  55. Tempero M, Plunkett W, Ruiz Van Haperen V et al. (2003) Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol 21: 3402–8

    Article  CAS  PubMed  Google Scholar 

  56. Ducreux M, Rougier P, Pignon JP et al. (2002) A randomised trial comparing 5-FU with 5-FU plus cisplatin in advanced pancreatic carcinoma. Ann Oncol 13: 1185–91

    Article  CAS  PubMed  Google Scholar 

  57. Levi FA, Tubiana-Mathieu N, Focan C et al. (2004) Chronomodulated versus constant rate infusional 5-fluoro-uracil with or without cisplatin in patients with advanced or metastatic pancreatic cancer. A multicenter randomized trial of the Chronotherapy Group of the European Organisation for Research and Treatment of Cancer (EORTC 05962). J Clin Oncol 2214S: 4117

    Google Scholar 

  58. Taïeb J, Lecomte T, Ezenfis J et al. (2002) Chimiothérapie des adénocarcinomes du pancréas non résecables par 5-fluoro-uracile, acide folinique et cisplatine (LV5FU2-P). Gastroenterol Clin Biol 26: 605–9

    PubMed  Google Scholar 

  59. Van Laethem JL, Polus M, Marechal R et al. (2004) Gemcitabine and oxaliplatine (GEMOX) in gemcitabine-refractory advanced pancreatic cancer: A phase II study. J Clin Oncol 2214S: (abstract 4119)

    Google Scholar 

  60. Jacobs AD, Burris HA, Rivkin S et al. (2004) A randomized phase III study of rubitecan versus best choice in 409 patients with refractory pancreatic cancer: report from a North-American multi-center study. J Clin Oncol 2214S: 4013

    Google Scholar 

  61. Bertheault-Cvitkovic F, Levi F, Soussan S et al. (1993) Circadian rhythm-modulated chemotherapy with high-dose 5-fluoro-uracil: a pilot study in patients with pancreatic adenocarcinoma. Eur J Cancer 29A: 1851–4

    CAS  PubMed  Google Scholar 

  62. Maisey N, Chau I, Cunningham D et al. (2002) Multicenter randomized phase III trial comparing protracted venous infusion (PVI) fluoro-uracil (5-FU) with PVI 5-FU plus mitomycin in inoperable pancreatic cancer. J Clin Oncol 20: 3130–6

    Article  CAS  PubMed  Google Scholar 

  63. Xiong HQ, Rosenberg A, Lobuglio A et al. (2004) Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II trial. J Clin Oncol 22: 2610–6

    Article  CAS  PubMed  Google Scholar 

  64. Safran H, Ramanathan R, Schwartz J et al. (2001) Herceptin and gemcitabine for metastatic pancreatic cancers that overexpress HER-2/neu. Proc Am Soc Clin Oncol 20: 130a (abstract 517)

    Google Scholar 

  65. Moore MJ, Goldstein D, Hamm J et al. (2005) Erlotinib plus gemcitabine compared to gemcitabine alone in patients with advanced pancreatic cancer. Proc Am Soc Clin Oncol 23: 15 (abstract 1)

    Google Scholar 

  66. Kindler HL, Friberg G, Stadler WM et al. (2004) Bevacizumab plus gemcitabine in patients with advanced pancreatic cancer: updated results of a multi-center phase II trial. J Clin Oncol 2214S: 4009

    Google Scholar 

  67. Gaudernack G, Buanes T, Meo M et al. (2003) Clinical trials of a peptide based vaccine targeting telomerase. Proc Am Soc Clin Oncol 22: 166

    Google Scholar 

  68. Brett BT, Smith SC, Bouvier CV et al. (2002) Phase II study of anti-gastrin-17 antibodies, raised to G17DT, in advanced pancreatic cancer. J Clin Oncol 20: 4225–31

    Article  CAS  PubMed  Google Scholar 

Download references

Authors
  1. D. Malka
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. Desramé
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2006 Springer-Verlag France

About this chapter

Cite this chapter

Malka, D., Desramé, J. (2006). Cancer du pancréas exocrine. In: Les cancers digestifs. Oncologie Pratique. Springer, Paris. https://doi.org/10.1007/2-287-30874-1_9

Download citation

  • DOI: https://doi.org/10.1007/2-287-30874-1_9

  • Publisher Name: Springer, Paris

  • Print ISBN: 978-2-287-22087-6

  • Online ISBN: 978-2-287-30874-1

Publish with us

Policies and ethics

Search

Navigation